Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$112.20M$112.20M+34.5% vs Q3 2020 Net Income$29.55M$29.55M+654.0% vs Q3 2020 EPS Diluted$0.59$0.59+637.5% vs Q3 2020 Gross Profit$51,183,000+40.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,569,000−70.8% Free Cash Flowderived-$4,650,000N/M Margins · derivedGross margin45.6%+1.9 pt vs Q3 2020
Operating margin22.1%+17.9 pt vs Q3 2020
Net margin26.3%+21.6 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 9, 2021 · 40 d after period end